US 11,730,834 B2
Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
Jamey Weichert, Sun Prairie, WI (US); Paul Sondel, Madison, WI (US); Anatoly Pinchuk, Fitchburg, WI (US); Zachary Morris, Madison, WI (US); Mario Otto, Fitchburg, WI (US); Bryan Bednarz, Madison, WI (US); and Peter Carlson, Madison, WI (US)
Assigned to Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed on Jun. 29, 2020, as Appl. No. 16/914,563.
Application 16/914,563 is a continuation of application No. 15/658,535, filed on Jul. 25, 2017, granted, now 10,751,430.
Claims priority of provisional application 62/366,340, filed on Jul. 25, 2016.
Prior Publication US 2020/0330621 A1, Oct. 22, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C07K 16/30 (2006.01)
CPC A61K 51/0408 (2013.01) [A61K 9/0019 (2013.01); A61K 38/2013 (2013.01); A61K 39/39558 (2013.01); A61K 51/0497 (2013.01); C07K 16/3084 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/585 (2013.01)] 20 Claims
 
1. A method of treating a metastatic cancer in a subject, wherein the metastatic cancer comprises a primary malignant solid tumor and one or more metastatic tumors capable of causing concomitant immune tolerance, the method comprising the steps of:
(a) administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially taken up by and retained within malignant solid tumor tissue; and
(b) performing in situ tumor vaccination in the subject at the primary malignant solid tumor using one or more treatments capable of stimulating specific immune cells within the tumor microenvironment, wherein the one or more treatments comprise contacting the primary malignant solid tumor with a composition comprising one or more agents capable of stimulating specific immune cells within the tumor microenvironment;
whereby the concomitant immune tolerance caused by the metastatic tumors is prevented and the metastatic cancer is treated in the subject.